Figure 4.

MicroRNA (miR‐302/367 cluster regulates tumorigenesis and development through multiple mechanisms. The miR‐302/367 cluster has been implicated in several of the hallmarks of cancer through interactions with various molecules and pathways, and the members of this cluster function by classical and noncanonical mechanisms of miRNA action. Through the networks that regulate the above characteristics, this cluster can affect the biological behaviors of tumor cells and induce different outcomes of cancer cells. As numerous hallmarks of cancer are regulated by the miR‐302/367 cluster, there are a variety of candidates for cancer treatment that involve different molecular targets and strategies. ATRA, All‐trans retinoic acid; BMI, B cell‐specific Moloney murine leukemia virus integration site 1; CCND, cyclin D; CDK, cyclin‐dependent kinase; CXCR4, C‐X‐C chemokine receptor type 4; DCUN1D1, cullin neddylation 1 domain containing 1; E2F3, E2 transcription factor 3; EGFR, epidermal growth factor recptor; ER, estrogen receptor; ErbB4, Receptor tyrosine‐protein kinase erbB‐4; GCNF, germ cell nuclear factor; GSK‐3β, glycogen synthase kinase‐3β; IGF‐1R, insulin‐like growth factor 1 receptor; IL‐8, interleukin‐8; ITGAV, Integrin alpha‐V; Klf2, Kruppel like factor 2; LATS2, large tumor suppressor kinase 2; Mcl‐1, myeloid cell leukemia sequence 1; MEKK, MAP/ERK kinase kinase 1; MIAT, myocardial infarction‐associated transcript; MICA/B, major histocompatibility complex class I chain‐related proteins A and B; MTDH, metadherin; NR2F2, nuclear receptor subfamily 2 group F member 2; PRP‐1, proline‐rich polypeptide 1; RAB23, Ras‐related protein 23; RACK1, receptor for activated C‐kinase 1; RYR3, Ryanodine receptor 3; SDC1, syndecan 1; VE‐cadherin,  vascular E‐cadherin; YAP, Yes‐associated transcriptional regulator; ULBP2, UL16‐binding protein 2; ZEB1, zinc finger E‐boxbinding 1